Abbisko Therapeutics Secures FDA IND Clearance for Pan-KRAS Inhibitor ABSK211, Targeting Broad Spectrum of KRAS Alterations in Solid Tumors
Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that the U.S. Food and Drug Administration (FDA)...
LongBio Pharma Secures FDA IND Approval for Novel Anti-IgE Antibody LP-003 in Peanut Allergy, Expanding Global Allergic Disease Pipeline
LongBio Pharma (Suzhou) Co., Ltd. (HKG: 1779) announced that the clinical trial application for LP-003...
Pfizer and Astellas Secure FDA Approval for PADCEV-KEYTRUDA Combination as First Platinum-Free Neoadjuvant/Adjuvant Therapy for Muscle-Invasive Bladder Cancer
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced that the U.S. Food...
Takeda and Indonesian Government Launch $30 Million Plasma Ecosystem Initiative to Expand Access to Lifesaving Therapies
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) and the Indonesian Government announced a groundbreaking...
Sanofi Secures FDA Approval for Sarclisa Escena Subcutaneous Formulation, First Dual-Administration Anti-Cancer Therapy for Multiple Myeloma
Sanofi S.A. (NASDAQ: SNY) announced that the U.S. Food and Drug Administration (FDA) has approved...
Hansoh Pharma’s B7-H3 ADC Risvutatug Rezetecan Meets Primary Endpoint in Phase III SCLC Trial, Showing Significant Survival Benefit Over Topotecan
Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that Risvutatug Rezetecan (HS-20093), its proprietary B7-H3-targeted...
Roche Secures CE Mark for Elecsys IGRA TB Test, Delivering Automated Solution for Tuberculosis Infection Detection
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that its Elecsys IGRA TB test has...
InSilico Medicine Announces Strategic CNS Drug Discovery Collaboration with China Medical System, Eligible for RMB 1.2 Billion in Milestone Payments
InSilico Medicine (HKG: 3696) announced an additional strategic collaboration with China Medical System Holdings Limited...
TransThera Secures NMPA Approval for Phase 2 Trial of TT-00973 in Combination with Firmonertinib for EGFR-Mutant NSCLC
TransThera Sciences (Nanjing), Inc. (HKG: 2617) announced that China’s National Medical Products Administration (NMPA) has...
PegBio Partners with Rani Therapeutics on Oral Biologic Delivery Platform – Targeting Obesity and Metabolic Disease Candidates
PegBio Co., Ltd. (HKG: 2565) announced the signing of a memorandum of understanding (MOU) with...
Salubris Pharmaceuticals Secures NMPA IND Clearance for SAL0167 – Proprietary Cyclic Peptide Targeting Hyperlipidemia
Shenzhen Salubris Pharmaceuticals (SHE: 002294) announced that China’s National Medical Products Administration (NMPA) has cleared...
Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise
Simcere Pharmaceutical Group (HKG: 2096) announced a global drug discovery and development collaboration agreement with...
Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics
Zhejiang Conba Pharmaceutical Co., Ltd. (SHA: 600572) announced it has entered into a strategic licensing...
Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)
Jacobio Pharmaceuticals (HKG: 1167) announced that its portfolio company, Jacobio-Raikang, has received National Medical Products...
Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma
Haixi Pharmaceutical announced it has officially initiated its Phase III clinical trial (CTR20261818) evaluating C019199,...
Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
Astellas Pharma Inc. (TYO: 4503) announced that China’s National Medical Products Administration (NMPA) has accepted...
Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) announced that China’s National Medical Products Administration (NMPA)...
Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
Shenyang Xingqi Pharmaceutical Co., Ltd. (SHE: 300573) announced positive results from its Phase 2 clinical...
Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Chia Tai Tianqing Pharmaceutical (CTTQ) has...
Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Changchun High & New Technology Industry (Group) Inc. (SHE: 000661) announced that China’s National Medical...